Trials / Completed
CompletedNCT04820452
A Study of IBI302 in Patients With nAMD
A Multi-center, Randomized, Double-blind, Active-controlled Phase II Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Neovascular Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 231 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Low dose IBI302 | Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection |
| BIOLOGICAL | High dose IBI302 | High dose IBI302 intravitreal injection given as every other month after three loading monthly injection |
| DRUG | Aflibercept | Intraocular injection |
Timeline
- Start date
- 2021-04-28
- Primary completion
- 2023-01-13
- Completion
- 2023-01-13
- First posted
- 2021-03-29
- Last updated
- 2024-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04820452. Inclusion in this directory is not an endorsement.